On Monday, Shares of Ford Motor Co. (NYSE:F), gained 0.81% to $14.90.
Ford Motor Company Fund is sponsoring an Honor Flight to transport Louisville area veterans to the National World War II Memorial in Washington, D.C. on Saturday. The World War II Honor Flight veterans – all in their eighties and nineties – will be greeted at the national memorial by members of Congress and Ford employees.
Ford Fund, the philanthropic arm of Ford Motor Company, is covering the cost of the trip to Washington, D.C. for about 70 veterans from Louisville and Kentucky to experience national memorials dedicated in their honor. The trip was organized by Honor Flight Bluegrass, the Kentucky hub of the Honor Flight Network, and coincides with the 71st anniversary of D-Day, the pivotal Allied invasion of Europe during World War II.
This is the third year in a row Ford has sponsored an Honor Flight for Louisville-area veterans. Ford’s support of military veterans dates back more than 90 years, when Henry Ford organized a cross-country caravan of 50 Model T Fords to take disabled veterans to the 1922 national convention of the Disabled American Veterans in San Francisco. Since 1974, Ford and Ford Fund have offered more than $8 million to veterans’ organizations, counting support for the National World War II Memorial.
Ford Motor Company manufactures and distributes automobiles worldwide. The company operates through two sectors, Automotive and Financial Services. The Automotive sector develops, manufactures, distributes, and services vehicles, parts, and accessories.
Shares of Palatin Technologies Inc. (NYSEMKT:PTN), inclined 15% to $1.15, during its last trading session, after Food and Drug Administration advisory panel voted 18-6 to approve a drug called flibanserin that treats low libido in women.
While Palatin does not make flibanserin, which is being developed by private pharmaceutical company Sprout Pharmaceuticals, it does make a version of the drug called bremelanotide.
Though the treatment has been dubbed the ‘female viagra’, it does not work in the same way as the popular male erectile dysfunction treatment does.
Palatin Technologies, Inc., a biopharmaceutical company, develops peptide therapeutics for the treatment of diseases. The company’s clinical development product is Bremelanotide, a peptide melanocortin receptor agonist that has accomplished Phase 2B clinical trial for the treatment of female sexual dysfunction (FSD).
At the end of Monday’s trade, Shares of MetLife, Inc. (NYSE:MET), lost -0.20% to $54.34.
MetLife Inc. declared a tender offer for any and all of its 60,000,000 outstanding shares of 6.500% Non-Cumulative Preferred Stock, Series B (CUSIP No. 59156R603), par value $0.01 per share and liquidation preference $25.00 per share (the “Series B Preferred Shares”). The tender offer is being made solely following the Offer to Purchase dated June 1, 2015 and the accompanying Letter of Transmittal. The terms and conditions of the tender offer are more fully set forth in those documents.
Upon and subject to the conditions set forth in the Offer to Purchase, MetLife is offering to pay a purchase price of $25.00 per Series B Preferred Share, plus an amount equal to accrued, unpaid and undeclared dividends from, and counting June 15, 2015, to, but not taking into account, the settlement date for the tender offer, for Series B Preferred Shares properly tendered and not properly withdrawn. MetLife presently anticipates the settlement date of the tender offer to be June 29, 2015.
MetLife, Inc. provides life insurance, annuities, employee benefits, and asset administration products in the United States, Japan, Latin America, Asia, Europe, and the Middle East. It operates in six segments: Retail; Group, Voluntary & Worksite Benefits; Corporate Benefit Funding; Latin America; Asia; and Europe, the Middle East and Africa.
Finally, Halcón Resources Corporation (NYSE:HK), ended its last trade with 5.88% surge, and closed at $1.26, despite oil fell by 1 percent or more on Monday on a slump in Chinese demand and worries that OPEC’s decision to pump crude without restraint could prolong the current supply glut, although a weaker dollar limited losses.
Halcón Resources Corporation, an independent energy company, is engaged in the acquisition, production, exploration, and development of onshore oil and natural gas properties in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
